MARLBOROUGH, Mass.–(BUSINESS WIRE)–Sep. 14, 2020–
Hologic, Inc. (Nasdaq: HOLX) equipped as of late that it has priced its beforehand equipped non-public offering of $950 million aggregate predominant quantity of 3.250% senior notes due 2029 at a challenge discover of $1,000 per $1,000. The 2029 notes will be unsecured duties of the Company and will probably be guaranteed by determined subsidiaries. The offering is anticipated to shut on September 28, 2020, field to musty closing prerequisites.
Hologic intends to thunder the proceeds of the offering and available cash to refinance its existing 4.375% senior unsecured notes due 2025 and can thunder recent cash to pay transaction-linked originate-total premiums, expenses and charges.
The 2029 notes might probably well perhaps not be registered below the Securities Act of 1933, as amended, or any converse securities regulations. Unless so registered, the securities might probably well perhaps simply not be equipped or sold in the United States with the exception of pursuant to an exemption from, or in a transaction not field to, the registration requirements of the Securities Act and relevant converse securities regulations. The 2029 notes are being equipped solely to licensed institutional investors in reliance on Rule 144A below the Securities Act, and outdoor the United States in step with Law S below the Securities Act.
This press release is neither a proposal to sell nor a solicitation of a proposal to seize any of these securities, nor shall there be any provide, solicitation or sale of these securities in any jurisdiction the attach the provide, solicitation or sale will not be permitted.
About Hologic, Inc.
Hologic, Inc. is an modern scientific abilities firm essentially centered on enhancing women folk’s health and neatly-being by intention of early detection and medicines.
Hologic, The Science of Certain, and associated emblems are emblems and/or registered emblems of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries
This files release accommodates forward-trying files that entails risks and uncertainties, at the side of statements about the Company’s plans, wishes, expectations and intentions. Such statements embody, without limitation, the Company’s scheme to field the 2029 notes and the thunder of proceeds of the offering. These forward-trying statements are field to identified and unknown risks and uncertainties that will probably well perhaps scheme proper results to differ materially from these expressed or implied by such statements. The offering might probably well perhaps simply additionally be adversely suffering from prevailing credit rating markets, which were field to vital volatility, or detrimental adjustments to Hologic’s replace or possibilities. Hologic cannot guarantee this might probably well well simply total the issuance of the 2029 notes on edifying phrases, if in any admire. The hazards included above are not exhaustive. Totally quite quite lots of factors that will probably well perhaps adversely impact the Company’s replace and possibilities are described in the filings made by Hologic with the SEC. Hologic expressly disclaims any responsibility or endeavor to release publicly any updates or revisions to any such statements presented herein to explain any alternate in expectations or any alternate in events, prerequisites or conditions on which any such statements are essentially based.
Source: Hologic, Inc.
Seek provide model on businesswire.com:
Michael WattsVice President, Investor Family and Company Communications
Source: Hologic, Inc.
Vice President, Investor Family and Company Communications